Reduce OCS use
Nucala offers proven asthma control with a reduction in maintenance OCS use for your patients with severe eosinophilic asthma.8,9
Internet Explorer is no longer supported.
To provide you with the best possible experience, please switch to a supported browser e.g.
has been added to your basket
Explore how Nucala can reduce clinically significant exacerbations in your patients with severe eosinophilic asthma1-3
Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older.6
Nucala was generally well tolerated during the trial and safety outcomes were consistent with the outcomes from randomised control trials.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441
© 2021 GSK group of companies or its licensor.
Trademarks are owned by or licensed to the GSK group of companies.
July 2022 | PM-GB-MPL-WCNT-220003 (V1.0)